Medications

FDA: Pulmonary embolism risk up with tofacitinib 10 mg for RA

(HealthDay)—A safety clinical trial has revealed that tofacitinib (Xeljanz, Xeljanz XR) 10 mg twice daily is associated with an increased risk for pulmonary embolism (PE) and death among patients with rheumatoid arthritis ...

page 5 from 40